Navigation Links
Phase 2b Trial Shows Unique Lipid Efficacy Profile of Novel Compound to Reduce Elevated Triglyceride Levels
Date:2/29/2012

SAN DIEGO, Feb. 29, 2012 /PRNewswire/ -- Essentialis, Inc., today announced Phase 2b trial results for its investigational compound DCCR demonstrating a reduction in triglyceride (TG) levels by 30 to 40 percent in patients whose TG levels exceeded 500 mg/dL (Very High Triglycerides [VHTG]). The study included an arm combining DCCR with fenofibrate treatment (Abbott Laboratories' Trilipix® (fenofibric acid)); in the combination arm, DCCR was shown to be additive to fenofibrate for all lipid fractions except LDL-C. In contrast, a 2009 study of VHTG patients using prescription omega-3 fatty acid in combination with fenofibrate revealed no clinically important change compared to fenofibrate alone(1).

More than five million people in the United States have very high TG levels. This population is at elevated risk for a number of diseases, including acute pancreatitis, diabetes and cardiovascular events (e.g., sudden death, myocardial infarction, acute coronary syndrome, revascularization, stroke and atrial fibrillation).

"The results of this study contribute to the growing body of knowledge on the potential of DCCR as a triglyceride-lowering treatment," said Richard C. Pasternak, M.D., Essentialis board member and head of the Company's scientific advisory board. "These data clearly motivate us to advance DCCR into larger trials that may demonstrate benefit to patients with multiple disease risk factors."

In this Phase 2b double-blind, placebo-controlled study, subjects were included in one of two sub-groups. About half of the subjects were included in the atorvastatin combination sub-group, where they were randomized to receive either DCCR 290 mg or placebo in combination with atorvastatin (Pfizer Inc.'s Lipitor®) 20 mg for 18 weeks. The remaining subjects in the study were included in the monotherapy/fenofibrate combination subgroup, where they were randomized to receive either DCCR 290 mg or placebo for 12 weeks, followed by co-adm
'/>"/>

SOURCE Essentialis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... privately held medical device company, announced today that it ... Corporation (Tokyo Stock Exchange TYO: 8001) to sell its ... in Japan . ViewRay,s technology, the ... MRI-guided radiation therapy system that images and treats cancer ...
(Date:1/22/2015)... 2015  Uroplasty, Inc. (NASDAQ: UPI ), a medical ... products to treat voiding dysfunctions, today reported financial results ... Global revenue for the Company,s Urgent ® ... new quarterly revenue record, as compared to $3.9 million ...
(Date:1/22/2015)... Jan. 22, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" ... on Omega-3 therapies for cardiovascular disease and overall health is ... accomplishments in 2014 and its outlook for 2015 from the ... Shareholders, We would like to take this opportunity ...
Breaking Medicine Technology:ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7
... 2011 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) ... Company 31st Annual Health Care Conference on Wednesday, March 9, ...   Interested parties may access a live webcast ... http://www.onyx-pharm.com/view.cfm/32/Event-Calendar It is recommended that listeners ...
... March 2, 2011 Men who take non-steroidal anti-inflammatory drugs ... 2.4 times more likely to have erectile dysfunction compared to ... a Kaiser Permanente study published online in The Journal ... a trend toward this same finding, this observational study used ...
Cached Medicine Technology:Onyx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference 2Non-Steroidal Anti-Inflammatory Drugs Linked to Increased Risk of Erectile Dysfunction 2Non-Steroidal Anti-Inflammatory Drugs Linked to Increased Risk of Erectile Dysfunction 3
(Date:1/22/2015)... 2015 The U.S. Pharmacopeial Convention is ... of Clinical Pharmacy Services at North Carolina State’s College ... the 2015 Beal Award for Distinguished Volunteer Service—the organization’s ... on the contributions of volunteer experts to direct its ...
(Date:1/22/2015)... its top dressmaking technologies, has been a leading dress supplier ... latest designs of wedding dresses and launching a site-wide promotion ... the fresh new products are designed for 2015, and they ... All the clothes from LunaDress follow up with the latest ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Woodloch Pines, an ... has been selected by TripAdvisor as the number one best ... 6th best in the world for their annual Travelers’ Choice ... travel community . The website is home to millions of ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Padre Murphy's and ... supporter of Pro Player Health Alliance (PPHA). The ... Murphy's in getting everyone, including NFL greats, treated for obstructive ... the leading groups supporting the cause in the valley. The ...
(Date:1/22/2015)... 2015 The Incredible Bulk is a revolutionary ... increase lean muscle by up to 30lbs in less than ... of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , “Our ... step-by-step, scientific diet formula that allows the body to pack ...
Breaking Medicine News(10 mins):Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 2Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 3Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 4Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2
... Endo Pharmaceuticals (Nasdaq: ENDP ) announced today ... Merrill Lynch 2009 Health Care Conference on Wednesday, May 13, ... and Chief Executive Officer of Endo, will review the company,s ... can be accessed from Endo,s website at www.endo.com ...
... China, May 6 /PRNewswire-Asia/ -- China Medicine ... "the Company"), a developer,and a leading distributor ... Chinese medicines (TCM), nutritional and dietary supplements, ... that it will conduct,a conference call at ...
... Highlights:- Net service revenues increased 77% to $69.2 million- ... $58.7 million- Net income increased 118% to $5.6 million- ... 45% more shares outstandingLOUISVILLE, Ky., May 6 Almost ... regional provider of home health nursing services, announced today ...
... catch high percentage of skin cancers at Women,s Dermatologic ... As champions of sun safety and skin health, ... (WDS) provided free skin cancer screenings and education ... SC recently. In a busy day of outreach, local ...
... May 6 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... biopharmaceutical company focused on endocrinology and oncology, today reported ... three months ended March 31, 2009., ... partnership with sanofi-aventis for cetrorelix in benign,prostatic hyperplasia ("BPH") ...
... Align Technology, Inc. (Nasdaq: ALGN ) announced ... at two upcoming financial conferences. Both presentations, as noted below, ... of Align Technology,s website at http://investor.aligntech.com . An archived ... months. , Conference: Bank of ...
Cached Medicine News:Health News:Endo to Present at Bank of America and Merrill Lynch 2009 Health Care Conference 2Health News:Endo to Present at Bank of America and Merrill Lynch 2009 Health Care Conference 3Health News:Endo to Present at Bank of America and Merrill Lynch 2009 Health Care Conference 4Health News:China Medicine Announces Conference Call to Discuss First Quarter 2009 Results 2Health News:Almost Family Reports First Quarter 2009 Results 2Health News:Almost Family Reports First Quarter 2009 Results 3Health News:Almost Family Reports First Quarter 2009 Results 4Health News:Almost Family Reports First Quarter 2009 Results 5Health News:Almost Family Reports First Quarter 2009 Results 6Health News:Almost Family Reports First Quarter 2009 Results 7Health News:Almost Family Reports First Quarter 2009 Results 8Health News:Almost Family Reports First Quarter 2009 Results 9Health News:Almost Family Reports First Quarter 2009 Results 10Health News:Almost Family Reports First Quarter 2009 Results 11Health News:Almost Family Reports First Quarter 2009 Results 12Health News:Almost Family Reports First Quarter 2009 Results 13Health News:Almost Family Reports First Quarter 2009 Results 14Health News:South Carolina Dermatologists Win Tennis Fans' Attention With Free Skin Cancer Checks and Sun Safety Tips 2Health News:South Carolina Dermatologists Win Tennis Fans' Attention With Free Skin Cancer Checks and Sun Safety Tips 3Health News:AEterna Zentaris Reports First Quarter 2009 Financial and Operating Results 2Health News:AEterna Zentaris Reports First Quarter 2009 Financial and Operating Results 3Health News:AEterna Zentaris Reports First Quarter 2009 Financial and Operating Results 4Health News:AEterna Zentaris Reports First Quarter 2009 Financial and Operating Results 5Health News:AEterna Zentaris Reports First Quarter 2009 Financial and Operating Results 6Health News:AEterna Zentaris Reports First Quarter 2009 Financial and Operating Results 7Health News:Align Technology Executives to Present at Upcoming Financial Conferences 2
Developed in conjunction with Pierce E. Scranton, Jr., M.D., the Seattle Small Joint Arthroscopy Set offers meticulously designed instrumentation for elbow, foot, and ankle surgeries....
... The Smith & Nephew ECTRA II ... release the carpal tunnel ligament endoscopically, allowing ... proximal cutting, while minimizing endoscopic lens fogging ... the surgeon complete visualization and control. ECTRA ...
... Nephew ECTRA II systems permit the surgeon ... ligament endoscopically, allowing access via two portals ... endoscopic lens fogging with good air flow. ... and control. ECTRA knives permit the surgeon ...
... Shoulder Holder is used for positioning the ... position. The shoulder holder is adjustable with ... arm positions and sizes. The MITT allows ... arm in the shoulder holder during surgery. ...
Medicine Products: